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The aim of this study was to inhibit influenza virus M2 protein expression by mutating the
splicing signal of the M gene. Mutations were introduced into the GU dinucleotide sequence
at the 59-proximal splicing site of the M gene (corresponding to nt 52–53 of M cRNA).
Transfected cells expressing mutated M viral ribonucleoproteins failed to generate M2 mRNA.
Interestingly, recombinant viruses with mutations at the dinucleotide sequence were viable,
albeit attenuated, in cell culture. These recombinants failed to express M2 mRNA and M2
protein. These observations demonstrated that the GU invariant dinucleotide sequence at the
59-proximal splicing site of M gene is essential for M2 mRNA synthesis. These results also
indicated that the M2 ion-channel protein is critical, but not essential, for virus replication in cell
culture. This approach may provide a new way of producing attenuated influenza A virus.
INTRODUCTION
For cellular mRNA maturation, group II introns of RNA
polymerase II transcripts are excised by splicing. This event
occurs co-transcriptionally and recent evidence suggests
that the C-terminal heptad-repeat domain of RNA poly-
merase II recruits factors to facilitate this biological pro-
cess (McCracken et al., 1997; Hirose & Manley, 1998). For
transcripts that undergo the U2-type (or major-class)
splicing pathway, the accuracy and efficiency of splicing
have been attributed to several cis-acting sequence elements
and trans-acting factors. The trans-acting factors include
U1, U2 and U4–6 small nuclear ribonucleoproteins
(snRNPs) and splicing factors that interact specifically
with the pre-mRNA cis elements. The cis-acting elements
include consensus RNA sequences at the 59 and 39 splice
sites, a conserved branch point, a polypyrimidine tract and
a splicing enhancer and silencer (Miriami et al., 2002). Of
these sequences, the invariant GU and AG dinucleotides at
the 59 and 39 ends, respectively, of introns are known to
be critical for splicing (Nissim-Rafinia & Kerem, 2002).
Mutations at these highly conserved sequences impair
proper splicing, although less-conserved consensus motifs,
adjacent to both donor and acceptor sites, might also be
involved in the process (Hastings & Krainer, 2001).
The genome of influenza A virus contains eight RNA seg-
ments (vRNA) of negative polarity. Each segment associates
with the nucleoprotein (NP) and polymerase subunits (i.e.
PB2, PB1 and PA) to form a viral ribonucleoprotein (vRNP)
complex. Influenza A virus uses a different strategy from
eukaryotes for mRNA synthesis. The viral mRNA is gener-
ated exclusively by the vRNP (Huang et al., 1990; Fodor
et al., 1994; Poon et al., 1999; Leahy et al., 2001). With a
genome of less than 14 kb, the virus has developed several
strategies to expand its genome-coding capacity (Lamb
& Takeda, 2001). These strategies include translation of
unspliced, spliced (NS segment) and alternatively spliced
(M segment) mRNAs and bicistronic mRNAs (PB1 seg-
ment). Of these eight vRNA segments, the M1 mRNA
generated from the M vRNP can further undergo alter-
native splicing to generate two different spliced viral mRNA
molecules (Inglis & Brown, 1981). The influenza A virus M
gene has two alternative 59 splice sites: a proximal 59 splice
site (corresponding to nt 52–53 of M cRNA), producing
M2 mRNA, and a distal 59 splice site (corresponding to
nt 12–13 of M cRNA), producing M3 mRNA (Shih et al.,
1995). It has been noted that M3 mRNA has almost no
coding capacity, whereas M1 and M2 mRNAs encode
structural and ion-channel proteins, respectively (Valcarcel
et al., 1991). The choice of alternative splicing sites is
suggested to be controlled by the viral polymerase (Shih
et al., 1995) and related to a host splicing factor (Shih &
Krug, 1996).
The splicing of influenza A virus mRNA has been studied
via both in vitro and in vivo assays (Lamb & Lai, 1984;
Plotch & Krug, 1986; Agris et al., 1989; Alonso-Caplen &
Krug, 1991; Valcarcel et al., 1991, 1993; Nemeroff et al.,
1992; Shih et al., 1995; Shih & Krug, 1996). However, the
majority of these studies were based on transcripts that
were not synthesized by vRNPs. Sequence analyses of the
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influenza M and NS genes have shown that the viral introns
possess typical features of U2-type splicing sequences,
suggesting that the viral introns can be excised by U2-type
spliceosomes. In particular, the introns of the M and NS
genes contain invariant GU and AG dinucleotides at the 59
and 39 ends, respectively (Lamb & Lai, 1980). In vitro
experiments have shown that small nuclear RNPs can bind
to viral-like mRNA transcripts to form U2-type spliceo-
somes (Agris et al., 1989). In addition, M mRNA has also
been found to contain an enhancer sequence to facilitate the
binding of cellular splicing factors (Shih & Krug, 1996).
In this study, we tried to inhibit M2 protein expression by
introducing mutations at the 59-proximal splicing site of
the M gene. In addition, we investigated the effect of
mutations on the invariant GU dinucleotide at the 59-
proximal splicing site of the M gene. Rather than using
classical in vitro splicing systems or viral-like RNA tran-
scripts in our study, the viral transcripts we studied were
generated entirely from recombinant vRNPs by using in
vivo systems. We found that mutation of the dinucleotide
sequence abolished splicing for M2 mRNA production.
Furthermore, recombinant viruses with mutations at this
unique sequence were attenuated in cell culture and failed
to express M2 ion-channel protein.
METHODS
Cell culture and viruses. 293T human embryonic kidney cells
and Madin–Darby canine kidney (MDCK) cells were maintained in
minimum essential medium (MEM) supplemented with 10% fetal
calf serum (FCS) and 1% penicillin and streptomycin (P/S) at 37 uC
in 5% CO2. Influenza A/WSN/33 (H1N1) virus and its derivatives
were propagated routinely in MDCK cells. For virus-stock preparation,
MDCK cells were infected with virus at an m.o.i. of 0?01. Progeny
virus was harvested at 3 days post-infection. Routine haemagglutinin
(HA) tests and plaque assays were used to measure the viral titre.
Construction of M vRNA expression plasmids with mutations
at the invariant 5§ GU at the 5§-proximal splicing site.
Plasmids pPOLI-M-RT (Fodor et al., 1999, 2002) and pHW187-M
(Hoffmann et al., 2000) were used to express M vRNA of influenza
A/WSN/33 virus. Mutations at the 59-proximal GU splicing sequence
were introduced into these plasmids by inverse PCR techniques and
all mutated sequences were confirmed by DNA sequencing.
Expression of M vRNP in transfected cells. Plasmids pcDNA-
PB2, pcDNA-PB1, pcDNA-PA, pcDNA-NP and pPOLI-M-RT were
used to express M vRNP of influenza A/WSN/33 virus in transfected
cells (Fodor et al., 1999, 2002). Briefly, 1 mg of each of the plasmids
was transfected into 293T cells by using Lipofectamine 2000
(Invitrogen) as instructed by the manufacturer. The medium of
transfected cells was replaced by MEM with 10% FCS and 1% P/S
at 24 h post-transfection.
Generation of recombinant influenza viruses. To generate
recombinant influenza A/WSN/33 virus, eight plasmids (pHW181-
PB2, pHW182-PB1, pHW183-PA, pHW184-HA, pHW185-NP,
pHW186-NA, pHW187-M and pHW188-NS) were used in this
study (Hoffmann et al., 2000). Transfection experiments were per-
formed as described by Hoffmann et al. (2000).
RNA extraction and cDNA synthesis. Total RNA from trans-
fected or infected cells was harvested by using an RNeasy Mini kit
(Qiagen). In a typical reverse-transcription reaction, 3 mg total RNA
was reverse-transcribed into cDNA by SuperScript II reverse tran-
scriptase (Invitrogen). For the detection of vRNA, 400 ng vRNA-
specific primer complementary to the 39 end of vRNA (Hoffmann
et al., 2001) was used in reverse-transcription reactions. By contrast,
for the detection of M mRNA molecules, 20 pmol M mRNA-specific
primer (59-TTTTTTTTTTTTTTTACTC-39; underlined sequence
corresponds to nt 23–26 of the M vRNA) was used in reverse-
transcription reactions.
Quantitative RT-PCR assays for vRNA and mRNA. For quanti-
fication of M vRNA and mRNA, a SYBR green-based real-time PCR
method was employed. Real-time PCR experiments were performed
by using a LightCycler (Roche). Plasmids containing the target
sequence were used as positive controls. Primers for the M vRNA
and M1 mRNA were 59-GACCAATCCTGTCACCTC-39 (corres-
ponding to nt 171–188 of the M cRNA) and 59-GATCTCCGT-
TCCCATTAAGAG-39 (corresponding to nt 735–755 of the M
vRNA). For M2 and M3 mRNA detection, intron-spanning primers
were used. Primers for the M2 RNA were 59-GAGGTCGAAAC-
GCCTAT-39 (underlined sequence corresponds to nt 41–51 of the
M cRNA, italic sequence corresponds to nt 740–745 of the M
cRNA) and 59-CTCCAGCTCTATGTTGACAAA-39 (corresponding
to nt 24–44 of the M vRNA). Primers for the M3 mRNA were 59-
CATAGCAAAAGCAGGCCTA-39 (underlined sequence corresponds
to the first 11 nt of the M cRNA, italic sequence corresponds to nt
740–744 of the M cRNA) and 59-CATAGACTCTGGCACTCC-39
(underlined sequence corresponds to nt 102–116 of the M vRNA).
The amplification program started with one cycle at 95 uC for
10 min, followed by 40 cycles of 95 uC for 10 s, 58 uC for 5 s (56 uC
for M3 mRNA detection) and 72 uC for 15 s. The specificity of the
assay was confirmed by melting-curve analysis at the end of each run
(65–95 uC, 0?1 uC s21). Amplified products were further analysed by
agarose-gel electrophoresis and sequencing.
Indirect immunostaining of M2 protein. Confluent monolayers
of MDCK cells grown on glass coverslips were washed with PBS and
infected at an m.o.i. of 1 with influenza A viruses. Infected cells
were harvested at 8 h post-infection, washed twice in PBS and fixed
in 4% paraformaldehyde in PBS. Fixed cells were permeabilized
with 0?5% Triton X-100 in PBS for 30 min, followed by two washes
in PBS. Cells were then incubated with 14C2 mouse anti-M2 IgG
monoclonal antibody (mAb) (diluted 1 : 1000; Affinity Bioreagents)
overnight at 4 uC. After two washes in PBS with 0?01% Triton
X-100, cells were incubated with rabbit anti-mouse antibody con-
jugated with fluorescein isothiocyanate (diluted 1 : 100; Zymed
Laboratories) for 1 h at room temperature. Samples were washed
twice in PBS containing 0?01% Triton X-100 and counterstained for
1 min with propidium iodide solution (BD Biosciences Pharmingen)
for DNA staining. After two more washes with PBS, coverslips were
mounted by using ProLong anti-fading reagent (Molecular Probes).
The surface fluorescence of cells was observed with a Zeiss Axiophot
Microscope and images were taken by using a Leica CCD camera.
Virus purification and Western blot analysis. MDCK cells were
infected with wild-type or mutant virus at an m.o.i. of 0?01. Virus
was harvested at 3 days post-infection and purified by using sucrose
gradients as described previously (Poon et al., 2000). Purified virus
was lysed in lysis buffer [0?6 M KCl, 50 mM Tris/HCl (pH 7?5),
0?5% Triton X-100]. Viral lysates were analysed by 12% SDS-PAGE
and transferred to a PVDF membrane (Amersham Biosciences).
Transferred membrane was first blocked for 1 h at room tempera-
ture with PBS containing 5% skimmed milk and 0?1% Tween 20
(Sigma, ICI Americas) followed by overnight incubation with 14C2
mouse anti-M2 IgG mAb (Affinity Bioreagents). The membrane was
washed three times with PBS containing 0?1% Tween 20 and then
incubated for 1 h at room temperature with a 1 : 5000 dilution of
horseradish peroxidase-conjugated goat anti-mouse IgG antibody
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(Zymed Laboratories). Signals were detected by using the Western
Immunoblot ECL Plus detection system, following the manufac-
turer’s instructions (Amersham Biosciences).
RESULTS
Mutated M vRNA fails to produced M2 mRNA in
transfected cells
In this study, we first used a plasmid-based reverse-genetics
system in our initial investigation (Fodor et al., 1999). To
determine whether the GU dinucleotide at the 59-proximal
splicing site of M gene was essential for the generation of
M2 mRNA, mutated vRNA expression plasmids with all
possible combinations of dinucleotide sequences were
generated. The mutated M vRNA expression plasmid and
four viral protein expression plasmids encoding PB2, PB1,
PA and NP were co-transfected into 293T cells to generate
M vRNPs. At 3 days post-transfection, vRNA and M1–
M3 mRNA generated from the transfected cells were
detected by corresponding RT-PCR assays. As shown in
Fig. 1, M vRNA could be found in the wild-type and all
mutants, showing that the introduced mutations did not
alter vRNA expression. M1 mRNA was detected in cells
transfected with wild-type or mutated constructs (Fig. 1,
row 2). In the presence of recombinant RNP expression,
wild-type M1 mRNA could be spliced into M2 or
M3 mRNA as expected (Fig. 1, rows 3 and 4) (Shih et al.,
1995; Shih & Krug, 1996). By contrast, M2 mRNA mole-
cules could not be detected in cells transfected with the
mutated constructs (Fig. 1, row 3). All of the mutated
constructs were able to yield M3 mRNA (Fig. 1, row 4).
These results suggested that mutations at the 59-proximal
splicing site specifically inhibited splicing for M2 mRNA
but not for M3 mRNA.
Generation of recombinant viruses with
mutations at the 5§-proximal splicing site
To investigate whether our studied mutations would be
detrimental to the viability of influenza A virus, we used a
reverse-genetics system to generate recombinant viruses
with the above mutations. Of 15 possible mutations, only
infectious recombinant viruses with AU, CU and UU
dinucleotide sequences could be generated. Interestingly,
these three mutations were all silent for M1 protein
expression. By contrast, all of the other mutations altered
aa 9 or 10 of the M1 protein, suggesting that these amino
acid residues are critical for influenza virus viability.
From our transfection experiments (Fig. 1), we demon-
strated that mutations at the 59-proximal splicing site
inhibited M2 mRNA synthesis. It was therefore of interest
to test whether these recombinant viruses also failed to
produce M2 mRNA. Two of the mutated viruses (AU and
CU) were selected for further analysis. MDCK cells were
infected by wild-type or mutants at an m.o.i. of 2. Total
RNA from infected cells was harvested at various time
points post-infection. The amounts of M1, M2 and
M3 mRNA in these samples were quantified by real-time
RT-PCR. Consistent with the observations deduced from
the transfection experiments, M vRNA (not shown),
M1 mRNA and M3 mRNA were detectable in all samples
(Fig. 2a), indicating that these mutated vRNA segments
were templates for viral transcription and replication in
infected MDCK cells. By contrast, M2 mRNA could only
be detected in MDCK cells infected with wild-type virus,
but not with the mutants.
With the quantitative data deduced from the real-time
PCR assays, we also estimated the relative proportions of
M1–M3 mRNA species in infected cells. In agreement with
Fig. 1. Detection of M vRNA and mRNA in transfected cells. M vRNA (123 bp), M1 mRNA (123 bp) and M3 mRNA
(204 bp) signals were observed in all samples. By contrast, M2 mRNA (276 bp) was only detected in the wild-type (WT)
sample (GU). Mutations introduced into the M vRNA expression plasmid are indicated. M, DNA markers;+, cDNA from virus-
infected cells; ”, negative water control. The faint M3 mRNA signal from the mutant UU was due to a sample-loading problem.
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previous studies (Valcarcel et al., 1991), the amount of M2
generated from wild-type-infected cells increased with time
(Fig. 2b). At 2 h post-infection, M2 mRNA comprised
about 8% of mRNA generated from the M vRNP (Fig. 2b).
At 16 h post-infection, 17% of mRNA derived from M
vRNA was M2 mRNA (Fig. 2b).
Recombinant viruses with mutations at the
5§-proximal splicing site are attenuated
Viruses with mutations at the 59-proximal splicing site
failed to synthesize spliced M2 mRNA. Although these
mutants were able to replicate in cell culture, they could
only produce pinpoint plaques when grown onMDCK cells.
The plaque sizes of the mutants (~0?5 mm diameter)
were three to four times smaller than those of the wild-
type (Fig. 3a). To characterize the growth properties of
these mutants in detail, MDCK cells were infected with the
mutant viruses at an m.o.i. of 0?01. At various time points
post-infection, the number of infectious progeny viral
particles released into the medium was determined by
plaque assay. The maximum viral titres of these mutants
were about 2 log units lower than that of the wild-type
(Fig. 3b). In addition, we determined the stability of these
mutations by passaging the mutants in MDCK cells 10
times. The desired mutations were all retained, indicating
that the introduced mutations were stable in routine cell
culture. These results suggested that, at least under cell-
culture conditions, M2 protein might not be absolutely
essential for virus replication. However, our results also
indicated that lack of M2 protein expression severely
affected growth of the virus.
M2 mutants fail to produce M2 ion-channel
protein
The splicing mutants failed to produce detectable M2
mRNA in infected cells, suggesting that these mutants
Fig. 2. Detection of M mRNA in infected cells. (a) Detection of M1–M3 mRNA in infected cells by RT-PCR. Total RNA from
cells infected by wild-type (WT) or mutants (AU or CU) was harvested at the indicated time points post-infection. Signals for
the PCR products were captured by using different exposure time and thus do not correlate to the amount of targeted RNA in
the sample. M, DNA markers; +, cDNA from virus-infected cells; ”, negative water control. (b) Relative proportions of M1
(empty bars), M2 (hatched bars) and M3 (filled bars) mRNA derived from the wild-type (GU) or mutated (AU and CU) M
vRNA. Data were deduced from two or more independent experiments.
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might not be able to synthesize M2 ion-channel protein. To
test this possibility, we examined M2 protein expression
in infected cells by indirect immunofluorescence. By using
an M2-specific mAb, a pattern of immunofluorescence
signals similar to that described by others (Hughey et al.,
1992) was observed in wild-type-infected cells (Fig. 4a).
However, none of the splicing mutants was found to
express M2 protein in infected cells (Fig. 4a). We also used
purified viral particles to confirm the above observations by
Western blot analysis. As shown in Fig. 4(b, lower panel),
M2 protein was only detected in the purified wild-type
virion and not in the mutants. By contrast, the amount of
M1 protein detected in these viruses was similar (Fig. 4b,
upper panel), indicating that similar amounts of virion
were used in the analysis.
To validate these findings further, we also attempted to
detect M2 protein expressed from recombinant M vRNPs
in transfected cells (i.e. the cells used in Fig. 1). Equal
amounts of cell lysates (Fig. 4c, upper panel) were analysed
by Western blotting as described above. Similar to the
results observed in virus-infected cells, M2 protein could
only be detected in cells transfected with the wild-type
construct (Fig. 4c, lower panel).
Virus morphology
M2 protein has been reported to be associated with virus
morphology (Roberts et al., 1998). We examined the
morphology of the splicing mutants by electron micro-
scopy. Both splicing mutants were spherical in shape and
morphologically indistinguishable from the wild-type (data
not shown). The sizes of the AU (138?83±15?70 nm,
n=100) and CU (134?98±14?42 nm, n=100) splicing
mutants were not statistically significantly different from
that of the wild-type (139?60±20?20 nm, n=100) (P>0?05,
Student’s t-test).
DISCUSSION
In this study, we inhibited M2 protein expression by intro-
ducing point mutations at the 59 end of the viral intron.
Sequence analysis of data available from the Influenza
Sequence Database (http://www.flu.lanl.gov) indicated that
this invariant dinucleotide sequence is conserved in all M
gene sequences. Thus, this GU sequence might be critical
for splicing of influenza transcripts. Indeed, none of our
mutants in this study was capable of generating M2 mRNA.
This inhibitory effect was highly specific and these
mutations did not affect the alternative splicing pathway
for M3 mRNA production. In eukaryotes, the majority
of cellular group II introns contain the invariant GU
dinucleotide at their 59 ends and are processed by the U2
splicing pathway (Burset et al., 2000). This GU dinucleo-
tide sequence is essential for the binding of U1 snRNP, a
critical event for U2-type spliceosome formation (Weber
& Aebi, 1988). Mutating this cellular GU dinucleotide
sequence often results in abnormal splicing processes and
gene expression (Aebi et al., 1986; Mount, 2000). Thus,
inhibition of M2 mRNA synthesis in the splicing mutants
might be due to disruption of the interaction between the
59-proximal splicing site and U1 snRNP.
Fig. 3. Attenuation of splicing mutants in
MDCK cells. (a) Plaque morphology of wild-
type (WT) and mutants (AU and CU) in
MDCK cells. (b) Growth curves of wild-type
(WT, n) and mutants (AU, %, and CU, &).
The amount of progeny viral particles gener-
ated from infected cells at the indicated time
points post-infection was quantified by plaque
assay. Results are shown as means±SD
from three independent experiments.
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None of the mutants was capable of synthesizing M2
ion-channel protein (Fig. 4a, b). The lack of M2 protein
expression in these mutants was validated by transfection
experiments (Fig. 4c). In addition, using a highly sensitive
quantitative RT-PCR assay with a detection limit of 10
copies per reaction (data not shown), we failed to detect
M2 mRNA from these mutants. Thus, it is highly unlikely
that these mutants expressed a low level of M2 protein in
infected cells. Although these mutants might have been
expected to revert to the wild-type by altering a single
nucleotide, they were found to be stable for at least 10
passages.
The p.f.u./HA ratios of our studied viruses were similar
(data not shown), suggesting that the lack of M2 expression
did not affect the formation of infectious viral particles.
Several previous findings have suggested that M2 protein
is not absolutely essential for influenza virus. First, recom-
binant viruses with defective M2 proteins have been gener-
ated by two independent groups (Watanabe et al., 2001;
Takeda et al., 2002). In addition, M2 protein has been
found not to be required for viral-like particle formation
(Mena et al., 1996), indicating that M2 protein is not
essential for the budding process. Here, we further demon-
strated that M2 protein expression is not required for
influenza virus to grow in cell culture. Interestingly, unlike
the M2 truncated mutants described by Watanabe et al.
(2001), our M2 splicing mutants showed similar growth
kinetics to the wild-type. This discrepancy might be partly
due to the different viral strains used in the studies.
Nonetheless, the recombinant viruses generated by us and
others (Takeda et al., 2002; Watanabe et al., 2002) were all
attenuated in animals or in cell culture, indicating that
the M2 protein plays an important role in efficient virus
replication.
In this study, we did not investigate the exact mechanism
of attenuation of the mutants. The ion-channel activity of
the M2 protein is essential for modulating the pH of the
trans-Golgi of virus-infected cells and the virion interior. In
the early phase of viral infection, the dissociation of vRNPs
from M1 protein is triggered by the proton influx from
WT CU
MockAU
U
U
I
I
Fig. 4. Splicing mutants fail to produce M2
protein. (a) Indirect immunostaining of M2
protein in infected cells. Cells infected with
wild-type (WT) or mutants (AU or CU) were
harvested at 8 h post-infection and stained
for M2 protein expression. Propidium iodide
was used as a counterstain and is shown in
red. Mock, Mock infection; I, infected cells;
U, uninfected cells. Bars, 30 mm. (b) Upper
panel: Coomassie blue-stained SDS gel
loaded with purified virions. The positions of
M1 and NP are indicated. Lower panel:
detection of M2 protein in purified virions by
Western blot analysis. The positive signal
for the M2 protein is indicated. An equal
amount (10 mg) of purified virions was
added in each lane. (c) Upper panel:
Coomassie blue-stained gel loaded with
lysates from transfected cells. Lower panel:
detection of M2 protein in 293T cells
expressing M vRNPs by Western blot analy-
sis. The positive signal for the M2 protein is
indicated. An equal amount (25 mg) of lysate
was added in each lane.
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endosomes to virion interiors via the M2 ion channel
(Bui et al., 1996). Using ion-channel inhibitors (e.g.
amantadine) to block the ion-channel activity could inhibit
the dissociation of M1 protein from vRNPs during viral
entry (Kemler et al., 1994). For some influenza virus
subtypes, these inhibitors could also induce conformational
changes of cleaved HA in the trans-Golgi network (Ciampor
et al., 1992; Takeuchi & Lamb, 1994). As the HA of our
parental strain (i.e. A/WSN/33) is not cleaved by endo-
genous proteinase (Goto & Kawaoka, 1998, 2000), it would
maintain its native structure within the trans-Golgi net-
work. Thus, the absence of M2 expression in our mutants
would have little impact on the HA conformation in
infected cells. A more plausible hypothesis is that, in the
absence of M2 ion-channel protein, vRNPs within virions
cannot be acidified by endosomes in the early stage of viral
infection. As a result, the dissociation of M1 protein from
vRNPs would be inhibited, thereby affecting normal virus
transcription and replication. Alternatively, the lack of M2
ion-channel protein might affect other biological processes
of the virus. Further work, such as studies of transcription
and replication kinetics and the nuclear importing of vRNP
of these mutants during early viral infection, is required
to elucidate the underlying reason for the attenuation of
these mutants.
Of the 15 splicing mutants, only those viruses containing a
GU to AU, CU or UU mutation could be rescued. Inter-
estingly, these three mutations did not alter the M1 protein-
coding sequence. By contrast, all of the other mutations
resulted in changes to aa 9 (Thr) or 10 (Tyr) of the M1
protein. Our results thus suggest that these two amino acid
residues are critical for the virus. These two residues are
located at the first helical structure of the M1 protein and
are involved in lipid-membrane binding (Sha & Luo, 1997).
Further investigation is required to elucidate the precise
effect of these mutations on the M1 protein.
Our results have demonstrated a novel method for gener-
ating attenuated influenza viruses. Sequence analyses of
influenza M mRNA indicated that the invariant dinucleo-
tide sequence is absolutely conserved (data not shown).
Thus, this approach can be used to generate attenuated
viruses with other genetic backgrounds. However, one
should be aware that this strategy might not be applicable
to strains that encode an intracellularly cleavable HA
(Sugrue et al., 1990; Takeuchi & Lamb, 1994).
Finally, the splicing mutants in this study might be used
to study other biological processes of influenza A virus.
For example, it has been suggested that the M1 and M2
proteins encoded by the M gene segment contribute to
filamentous virus morphology (Hughey et al., 1995; Roberts
et al., 1998; Bourmakina & Garcı´a-Sastre, 2003). The virus
strain used in this study (A/WSN/33) displayed a spherical
morphology and we did not observe any changes in virus
morphology in our mutants by electron microscopic
examination. However, it would be possible to delineate
the roles of the M1 and M2 genes in virus morphology by
applying similar mutations to strains that are predomi-
nantly filamentous in shape (Bourmakina & Garcı´a-Sastre,
2003; Elleman & Barclay, 2004).
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